Singapore legislation
Regulation 13E
of Central Provident Fund (Medisave Account Withdrawals) Regulations 2001
Regulation 13E
High‑cost drug treatment
Subregulation 1
A member may withdraw moneys from the member’s medisave account for the payment of any course of high‑cost drug treatment that starts on or after 1 October 2025, received by the member or the member’s dependant —
in any of the following approved medical institutions:
an approved hospital, as an in‑patient or out‑patient;
an approved community hospital, as an in‑patient;
an approved day hospital, as an in‑patient;
an approved convalescent hospital, as an in‑patient;
an approved in‑patient hospice, as an in‑patient;
an approved IPC provider, as an in‑patient;
an approved clinic, as an out‑patient;
an approved day hospice, as an out‑patient;
an approved hospital or approved day surgery centre, as part of any day surgical treatment;
at the patient’s home or in an approved MIC@Home treatment provider, as part of any approved MIC@Home treatment or qualifying combined treatment, as applicable; or
at the patient’s home from an approved home palliative care provider.
Subregulation 2
Subject to regulations 4, 21B, 21C, 21D and 21E, the total amount the member may withdraw under paragraph (1) for payment of each course of high‑cost drug treatment received by each patient must not exceed the lowest of the following amounts:
the amount specified in the third column of the Eighth Schedule in respect of the high‑cost drug treatment received by the patient for the clinical indication specified in the first column of that Schedule;
the total expenditure for the course of high‑cost drug treatment;
the total credit balance in the member’s medisave account.
Subregulation 3
For the purposes of this regulation, the start and end of a course of high‑cost drug treatment is determined by the applicable approved medical institution mentioned in paragraph (1)(a), approved MIC@Home treatment provider or approved home palliative care provider (as the case may be), based on the advice of an approved medical practitioner.
Subregulation 4
To avoid doubt, regulations 5, 6, 7, 8, 9, 9AA, 9A, 12A, 13B and 21 do not apply to high‑cost drug treatment.